Navigation Links
Maryland Performance Excellence Awards Program Announces Winners of Maryland Quality Awards
Date:3/24/2009

COLLEGE PARK, Md., March 24 /PRNewswire-USNewswire/ -- The University of Maryland's Maryland Performance Excellence Awards Program, in conjunction with U.S. Senators Barbara Mikulski and Benjamin Cardin, today announce the winners of the prestigious Maryland Quality Awards.

These awards honor role-model organizations that successfully implement systematic processes for continuous improvement and achieving outstanding results. Award recipients are evaluated rigorously by an independent board of examiners using the Baldrige Criteria for Performance Excellence, which measure an organization in seven areas: leadership; strategic planning; customer and market focus; measurement, analysis and knowledge management; workforce focus; process management; and results.

Award recipients include:

  • Maryland Quality Award -- Gold: Headquartered in Harford County, Custom Direct is a market leader in direct-to-consumer personalized printed products, security and fraud protection, financial documents, fulfillment items, phone support and direct marketing services. With a vision to become a world class organization with $250 million in revenue with less than 50 percent from checks, the organization has adopted the Baldrige Criteria for Performance Excellence and LEAN principles to create a culture of excellence for its 460+ associates, located in Maryland and Arkansas. Custom Direct was established in 1993 and is a wholly owned subsidiary of Edgestone Capital Fund III.
  • Maryland Quality Award -- Gold: Upper Chesapeake Health, a community-based, two-hospital, not-for-profit health system located in Harford County, has served more than three generations of patients with high quality health care since 1912. It owns and operates Upper Chesapeake Medical Center and Harford Memorial Hospital, both which are accredited by The Joint Commission (TJC). With its core val
    '/>"/>

SOURCE Maryland Technology Enterprise Institute
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. ADA Challenges Marylanders to Step Out to Fight Diabetes Epidemic
2. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
3. AARP Maryland Calls on President Bush Not to Veto SCHIP
4. Inhalant Abuse Prevention Program to Be Launched in Maryland Schools
5. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
6. CBaySystems Selected to Receive Deloittes 2007 Maryland Technology Fast 50 Award
7. Maryland Pharmacists Urge House Majority Leader Hoyer to Put Patients First
8. New Report: Increasing Marylands Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
9. GSA confers 2007 Joseph T. Freeman Award to University of Marylands Goldberg
10. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
11. Bald Valentine Offers Loving Tips in Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3